Search clinical trials for: BRAFV600-mutant,

Total 566 results

Pfizer

Terminated

An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis (POLARIS)

Brain Metastases

United States, Belgium, Australia, Argentina, Italy
Array BioPharma

Completed

Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations

Metastatic Colorectal Cancer

United States, Australia, Belgium, Canada, France, Israel, Italy, Netherlands, Singapore, Spain
Sidney Kimmel Comprehensive Cancer Center at Johns...
Genentech, Inc.

Withdrawn

Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma

Melanoma

United States
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Recruiting

A Study of ZG19018 in Patients With KRAS G12C Mutant Advanced Solid Tumors.

KRAS G12C Mutant Advanced Solid Tumors

China
Amgen

Active, not recruiting

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

KRAS p.G12C Mutant Advanced Solid Tumors

United States, France, Canada, Spain, Belgium, Korea, Republic of, Austria, Australia, Hungary, Greece, Germany, Japan, Romania, Switzerland, Brazil, Portugal
Providence Health & Services

Available

Intermediate-size IND for Treatment of KRAS G12V-mutant Tumors

KRAS G12V Mutant Advanced Epithelial Cancers
CCTU- Cancer Theme
Pierre Fabre Medicament

Not yet recruiting

Perioperative Encobini in BRAFV600 Mutant Stage III (B/C/D) or Oligometastatic Stage IV Melanoma (PREMIUM)

Melanoma | Cancer

United Kingdom
Cambridge University Hospitals NHS Foundation Trust
University of Oxford; National Institute for Health Research, United Kingdom; Oxford University Hospitals NHS Trust

Completed

Continuous vs Intermittent Dabrafenib Plus Trametinib in BRAFV600 Mutant Stage 3 Unresectable or Metastatic Melanoma (INTERIM)

Melanoma

United Kingdom
Melanoma Research Foundation Breakthrough Consortium
Genentech, Inc.

Terminated

Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma

Melanoma | Metastatic Melanoma

United States
Grupo Español Multidisciplinar de Melanoma

Completed

Translational Study for BRAFV600 Serum and Plasma Determination in Patients With BRAFV600 Metastatic Melanoma (BRAFV600)

Stage IV Skin Melanoma

Spain
Pfizer

Active, not recruiting

An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

United States, Spain, Netherlands, Korea, Republic of, Italy
National Institute of Allergy and Infectious Diseases...

Completed

Phase I Study of ETEC Vaccine

Gastroenteritis Escherichia Coli

United States
University Hospital, Rouen

Unknown

Correlation Between Circulating Tumour Markers Early Variations and Clinical Response in First Line Treatment of Metastatic Colorectal Cancer (COCA-MACS)

Metastatic Colorectal Cancer | Circulating Markers

France
Memorial Sloan Kettering Cancer Center
Array BioPharma

Completed

A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers

Advanced BRAF Mutant Cancers

United States
Asana BioSciences

Completed

A Study of ASN007 in Patients With Advanced Solid Tumors

Cancer | Neoplasm Metastasis | Pancreatic Cancer | Metastatic Cancer | Metastatic Lung Cancer | Pancreas Adenocarcinoma | Metastatic Melanoma | Colon Cancer | Colonic Neoplasms | Pancreas Cancer | Non Small Cell Lung Cancer Metastatic | Neoplasm | Pancreas Neoplasm | Metastatic Pancreatic Cancer | Metastatic Colon Cancer and other conditions

United States
GlaxoSmithKline
Pfizer

Completed

A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors

Cancer

United States
Pfizer

Completed

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

BRAF or NRAS Mutant Metastatic Melanoma

United States, Netherlands, Italy, Germany, Switzerland
Shanghai Kechow Pharma, Inc.

Not yet recruiting

Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

Colorectal Cancer Metastatic
Guangdong Association of Clinical Trials
Guangdong Provincial People's Hospital

Completed

Icotinib or Whole Brain Irradiation in EGFR-mutant Lung Cancer (BRAIN)

Non Small Cell Lung Cancer | Brain Metastasis

China
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute; Chugai Pharma USA

Active, not recruiting

RO5126766 for Patients With Advanced KRAS-Mutant Lung Cancer

Advanced Non-small Cell Lung Cancer

United States
Olivia Newton-John Cancer Research Institute
The Alfred; Austin Health; Peter MacCallum Cancer Centre, Australia; Royal Brisbane... and other collaborators

Recruiting

A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study) (I-FIRST)

Thyroid Cancer

Australia
University of Utah

Withdrawn

Radiation Use During Vemurafenib Treatment

Stage IV Melanoma | BRAFV600 Mutation

United States
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Advanced KRAS G12D Mutant Solid Tumors

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Phase I Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Advanced KRAS G12D Mutant Solid Tumors

China
National Cancer Institute, Naples

Active, not recruiting

Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer (STREAM)

Advanced Colorectal Cancer

Italy
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

Lung Cancer

United States
Hoffmann-La Roche

Terminated

A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma

Advanced BRAFV600 Wild-type Melanoma

United States, Korea, Republic of, Australia, Belgium, France, Russian Federation, Italy, Netherlands, Spain, United Kingdom, Brazil, Poland, Germany, Greece, Hungary
Millennium Pharmaceuticals, Inc.

Terminated

A Dose-Finding Study of Vedolizumab for Treatment of Steroid-Refractory Acute Intestinal Graft-Versus-Host Disease (GvHD) in Participants Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)

Allogeneic Hematopoietic Stem Cell Transplantation

United States, Belgium, Sweden, France, Norway
Suzhou Genhouse Bio Co., Ltd.
Shanghai East Hospital; Shandong Tumor Hospital

Recruiting

A Phase I/II Clinical Study to Evaluate The Safety, PK, PD of GH55 in Patients With MAPK Mutant Advanced Solid Tumors

Advanced Solid Tumors With MAPK Signal Pathway Mutant

China
Pfizer

Active, not recruiting

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Ovarian Cancer | NSCLC | Solid Tumors | Urothelial Cancer | Advanced Malignancies

Hungary, Spain, United States, Canada, Taiwan, Japan, Serbia, Italy, New Zealand, Australia, Mexico, Russian Federation, United Kingdom, France, Korea, Republic of, Belgium, Poland, Denmark, Israel
Peter MacCallum Cancer Centre, Australia

Recruiting

Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE (CELEBRATE)

Melanoma | Metastasis

Australia
National Cancer Institute (NCI)

Active, not recruiting

Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma

Astrocytoma, IDH-Mutant, Grade 2 | Astrocytoma, IDH-Mutant, Grade 3

United States
Memorial Sloan Kettering Cancer Center
Millennium Pharmaceuticals, Inc.

Completed

Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D

Non-Small Cell Lung Cancer

United States
Robert Ferris
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Head and Neck Cancer

Head and Neck Cancer

United States
Jacobio Pharmaceuticals Co., Ltd.

Recruiting

FIH Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation in China

NSCLC | Solid Tumor | CRC

China
Sabine Mueller, MD, PhD
National Cancer Institute (NCI); Dana-Farber Cancer Institute; Mithil Prasad... and other collaborators

Recruiting

ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors (PNOC023)

Glioblastoma | Recurrent Ependymoma | CNS Tumor | Diffuse Midline Glioma (DMG) | Recurrent Malignant Central Nervous System Neoplasm | Spinal Cord Glioma | Central Nervous System Tumor | World Health Organization (WHO) Grade III Glioma

United States, Switzerland
Southwest Oncology Group
National Cancer Institute (NCI); Roche-Genentech

Completed

S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer

Colorectal Cancer

United States
St George's, University of London
Novartis Vaccines; European Union; Richmond Pharmacology Limited

Terminated

Safety Study Of Nasal HIV Vaccine Adjuvanted With LTK63

HIV Infections

United Kingdom
GlaxoSmithKline

Completed

A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma

Melanoma

Australia, France, Germany, United States, Italy
Addario Lung Cancer Medical Institute

Withdrawn

PDX Models From EGFR Mutant Tumors

Non Small Cell Lung Cancer

United States
Pfizer

Terminated

LGX818 for Patients With BRAFV600 Mutated Tumors (SIGNATURE)

Solid Tumor | Hematologic Malignancies

United States
Jacobio Pharmaceuticals Co., Ltd.

Recruiting

JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation

NSCLC | Advanced Solid Tumor | CRC

United States
IRCCS Azienda Ospedaliero-Universitaria di Bologna

Terminated

Effects of Bosentan on Respiratory Mechanics

Pulmonary Hypertension

Italy
Chinese PLA General Hospital
Hutchison Medipharma Limited

Recruiting

Safety and Efficacy of Fruquintinib+FOLFIRI in RAS-mutated Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
Genentech, Inc.

Active, not recruiting

To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer

Breast Cancer | Solid Tumor

United States, France, Spain, United Kingdom, Canada
University of California, San Francisco
Novartis Pharmaceuticals; American Cancer Society, Inc.

Terminated

Trametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

United States
Pfizer

Completed

Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US (OCEANMIST)

Melanoma

United States
Hospices Civils de Lyon

Completed

Olaparib in Recurrent IDH-mutant Glioma (OLAGLI)

Recurrent IDH | Mutant High Grade Glioma

France
Mayo Clinic

Withdrawn

MANP in African Americans With Hypertension (MANP-2)

Hypertension, Resistant to Conventional Therapy

United States
Juan M Garcia-Gomez
Hospital Universitario 12 de Octubre; Hospital Clínico Universitario de Valencia

Recruiting

BIOhabitats: Biological Validation of Vascular Habitats Within Astrocytoma Grade 4 at Molecular, Cellular, and Histopathological Levels (BIOhabitats)

Glioblastoma | Glioblastoma Multiforme | High Grade Glioma | Astrocytoma, Grade IV | Glioblastoma, IDH-mutant | Glioblastoma, IDH-wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) Mutant

Spain

Search clinical trials for: BRAFV600-mutant,

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uzbekistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations